Disitamab vedotin (DV), a HER2‑targeted antibody‑drug conjugate, produced confirmed overall response rates of roughly 53–55% in a phase 2 cohort of previously treated metastatic urothelial carcinoma, data presented at the ASCO Genitourinary Cancers Symposium showed. Responses were similar across HER2‑positive and HER2‑low cohorts, with median progression‑free survival near 5.7 months. Investigators noted DV uses an MMAE payload distinct from other HER2 ADCs; the data add to a growing body of evidence that HER2‑directed ADCs can be active in bladder cancer and may broaden therapeutic options.